Biohaven Ltd. (BHVN)
NYSE NYSE Primary 
Biohaven Insiders Bet $33 Million on a Turnaround
When corporate executives make multi-million-dollar personal investments in the company they lead, it is one of the most potent signals an investor can receive. At Biohaven NYSE: BHVN, that signal has just been sent loud and clear.
Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA Verdict
BHVN's lead asset is Troriluzole, which is nearing a pivotal FDA decision by August 2025. The company also recently secured an additional $600 million financing through secured notes with Oberland Capital. Moreover, BHVN's pipeline is diverse, including other neurology, immunology, oncology, and obesity programs.
Why Biohaven Stock Plummeted by More Than 15% Today
On Friday's news that Biohaven (BHVN -15.34%) withdrew its application for a top investigational drug from an important regulator, investors aggressively traded out of the stock. The clinical-stage biotech was one of the biggest decliners in its industry, exiting Friday with a share price decline of over 15%.
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
Shares of early-stage biotech stocks, including Biohaven (BHVN -6.50%), Recursion Pharmaceuticals (RXRX -4.92%), and CRISPR Therapeutics (CRSP -2.05%), plunged in March, with the stocks down 35.3%, 29.6%, and 22.5%, respectively, according to data from S&P Global Market Intelligence.
Biohaven's Exciting Year Of Catalysts
Following Pfizer's acquisition, Biohaven's valuation surged from $300M at $7/share to over $4B at $42/share under Vlad Coric's leadership. Despite the significant valuation increase, substantial upside remains due to Biohaven's promising later-stage clinical assets with key catalysts expected in 2025. The investment thesis hinges on the potential success of these clinical assets, which could drive further valuation growth.
Why Biohaven Stock Triumphed on Tuesday
News of a big and important regulator's move was the electricity that powered Biohaven (BHVN 11.19%) stock to an 11%-plus gain on the second trading day of the week. Its leading investigational drug is now significantly closer to potential approval, and many are feeling bullish about the company.
Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck
Biohaven's NDA for Troriluzole in spinocerebellar ataxia was accepted by the FDA with Priority Review, potentially leading to approval in Q3 2025. BHV-7000, a selective Kv7 activator, is being studied for bipolar disorder and MDD, with data expected in 2025. The global major depressive disorder treatment market is expected to reach $14.96 billion by 2032.
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
On Monday, Biohaven Ltd. BHVN updated the taldefgrobep alfa development programs in Spinal Muscular Atrophy (SMA) and obesity.
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more than 300 points on Monday.
Biohaven's spinal muscular atrophy drug fails to meet main goal in study
Biohaven said on Monday its experimental treatment for spinal muscular atrophy, a rare nervous system dosorder, helped improve patients' motor function in a late-stage study, but failed to achieve statistical significance compared to placebo and standard of care.
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
The pivotal BHV4157-206-RWE study evaluating Biohaven's pipeline candidate, troriluzole, for treating spinocerebellar ataxia meets its primary endpoint.
Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
Biohaven Ltd. NYSE: BHVN has taken center stage in the biopharmaceutical sector after releasing positive results from its Phase 3 clinical trial for troriluzole, a drug being developed to treat spinocerebellar ataxia (SCA).
